Abstract
A precision medicine approach to haematological malignancies
Highlights
In The Lancet Haematology, Berend Snijder and colleagues[1] report interim results of their study evaluating the effect of ex-vivo drug sensitivity screening on the treatment of patients with refractory haematological malignancies
Using an automated immunofluorescence microscopybased platform named pharmacoscopy, the authors prospectively evaluated 48 patients with various haematological malignancies, 17 of whom received treatment guided by this approach
Given the inherent heterogeneity of this cohort, the investigators opted to compare the benefit of pharmacoscopy-guided treatment to the effect of previous treatments in the same patient
Summary
In The Lancet Haematology, Berend Snijder and colleagues[1] report interim results of their study evaluating the effect of ex-vivo drug sensitivity screening on the treatment of patients with refractory haematological malignancies. A precision medicine approach to haematological malignancies In The Lancet Haematology, Berend Snijder and colleagues[1] report interim results of their study evaluating the effect of ex-vivo drug sensitivity screening on the treatment of patients with refractory haematological malignancies. Using an automated immunofluorescence microscopybased platform named pharmacoscopy, the authors prospectively evaluated 48 patients with various haematological malignancies, 17 of whom received treatment guided by this approach.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
